Wolfram Brugger

15.6k citations
196 papers · 11.0k · 4 hit papers · h-index 51

Impact in

  • Genetics top 0.2%
    • Chronic Lymphocytic Leukemia Research
  • Immunology top 0.5%
    • Immunotherapy and Immune Responses
    • Immune Cell Function and Interaction

Papers in

    • CAR-T cell therapy research 17
    • Hematopoietic Stem Cell Transplantation 36
    • Acute Myeloid Leukemia Research 25

Wolfram Brugger

188 papers receiving 10.6k citations

Wolfram Brugger's Hit Papers

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial 2013 · 1.0k citations
1.0k0+9+18Years since publication2505007501000

Peers

Wolfram Brugger
Comparison fields: 5 of 121
  • Genetics 1.7k
  • Immunology 3.5k
  • Hematology 1.8k
  • Oncology 3.9k
  • Pathology and Forensic Medicine 2.1k
Replace Kenneth A. Foon with:
Kenneth A. Foon United States
Karen Pulford United Kingdom
Livio Trentin Italy
Paul J. Kurtin United States
Raymond R. Tubbs United States
Irwin D. Bernstein United States
Marco Bregni Italy
Giorgio Inghirami United States
Renato Zambello Italy
Ioannis Anagnostopoulos Germany
Wolfram Brugger relative to Kenneth A. Foon United States Kenneth A. Foon's profile →
Citations per field
00.5×1.5×2×
Kenneth A. Foon · 1×
Citations per year

Countries citing papers authored by Wolfram Brugger

Since Specialization
Citations

This map shows the geographic impact of Wolfram Brugger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wolfram Brugger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wolfram Brugger more than expected).

Fields of papers citing papers by Wolfram Brugger

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wolfram Brugger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wolfram Brugger. The network helps show where Wolfram Brugger may publish in the future.

Co-authors

The 25 scholars most cited alongside Wolfram Brugger, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Wolfram Brugger Line = papers co-authored together Wolfram Brugger links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 196 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
Hit paper breakdown →
20131013
2
Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study
Hit paper breakdown →
2010946
3
The Chemokine Receptor CXCR-4 Is Expressed on CD34+Hematopoietic Progenitors and Leukemic Cells and Mediates Transendothelial Migration Induced by Stromal Cell-Derived Factor-1
Hit paper breakdown →
1998557
4 2000460
5
Randomized Phase II Study of Erlotinib Plus Tivantinib Versus Erlotinib Plus Placebo in Previously Treated Non–Small-Cell Lung Cancer
Hit paper breakdown →
2011327
6 1994314
7 1999268
8 1999260
9 2011228
10 1990195
11 2006192
12 2010190
13
Heterogeneity among human bone marrow-derived mesenchymal stem cells and neural progenitor cells.
2003190
14 2010186
15 2011179
16 2002177
17
The epithelial tumor antigen MUC1 is expressed in hematological malignancies and is recognized by MUC1-specific cytotoxic T-lymphocytes.
2001173
18
Adoptive transfer of tumor cytotoxic macrophages generated in vitro from circulating blood monocytes: a new approach to cancer immunotherapy.
1990171
19 2001160
20 1999158

About Wolfram Brugger

Wolfram Brugger is a scholar working on Oncology, Hematology, Immunology, Molecular Biology and Pathology and Forensic Medicine, having authored 196 papers that have together received 11.0k indexed citations. Recurring topics across this work include Immunotherapy and Immune Responses (39 papers), Hematopoietic Stem Cell Transplantation (36 papers), Lymphoma Diagnosis and Treatment (35 papers), Acute Myeloid Leukemia Research (25 papers), Chronic Lymphocytic Leukemia Research (19 papers), CAR-T cell therapy research (17 papers), Lung Cancer Treatments and Mutations (16 papers) and Immune cells in cancer (12 papers). The work is most often cited by research in Genetics (1.7k citations), Immunology (3.5k citations), Hematology (1.8k citations), Oncology (3.9k citations) and Pathology and Forensic Medicine (2.1k citations). Wolfram Brugger has collaborated with scholars based in Germany, United States and United Kingdom. Frequent co-authors include Lothar Kanz, Peter Brossart, Robert Möhle, Volker L. Reichardt, Frank Grünebach, Gernot Stuhler, Hans‐Jörg Bühring, Frank Bautz, Stefan Wirths and Shahin Rafii. Their work appears in journals such as Blood, Journal of Clinical Oncology, Annals of Oncology, Experimental Hematology and Annals of the New York Academy of Sciences.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact